⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9569803 | 1.00 | TSHR (0.69) | — | |
| SCHEMBL29165133 | 1.00 | TSHR (0.69) | — | |
| SCHEMBL31154544 | 1.00 | TSHR (0.69) | — | |
| SCHEMBL6446892 | 1.00 | TSHR (0.69) | — | |
| Hydrochloric Acid SCHEMBL29063477 | 0.97 | ALDH1A1 (0.65) | — | |
| Hydrochloric Acid SCHEMBL29063506 | 0.97 | ALDH1A1 (0.65) | — | |
| Hydrochloric Acid SCHEMBL29063587 | 0.97 | ALDH1A1 (0.65) | — | |
| Hydrochloric Acid SCHEMBL10478935 | 0.97 | ALDH1A1 (0.65) | — | |
| Hydrochloric Acid SCHEMBL29063593 | 0.97 | ALDH1A1 (0.65) | — | |
| SCHEMBL6187154 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6858679-B2 | Compositions providing improved functionalization of terminal anions and processes for improved functionalization of terminal anions | FMC CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| US-6642231-B2 | Antineoplastic agents, treatment for neuronal injury and degeneration | AVENTIS PHARMACEUTICALS INC. | 2003-11-04 | — | — | US | disclosed |
| EP-1028982-B1 | COMPOSITIONS PROVIDING IMPROVED FUNCTIONALIZATION OF TERMINAL ANIONS AND PROCESSES FOR IMPROVED FUNCTIONALIZATION OF TERMINAL ANIONS | FMC CORP (US) | 2003-10-29 | — | — | EP | disclosed |
| EP-1056744-B1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMA INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030153693-A1 | Compositions providing improved functionalization of terminal anions and processes for improved functionalization of terminal anions | QUIRK RODERIC PAUL (US) | 2003-08-14 | — | — | US | disclosed |
| US-6605564-B1 | Anionic polymerization initiators and salt additives selected from sodium chloride, sodium iodide, potassium chloride, potassium t-butoxide, for increasing the efficiency of reactions between living polymer anions and electrophiles | FMC CORPORATION | 2003-08-12 | — | — | US | disclosed |
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AVENTISUB II INC. | 2003-06-05 | — | — | US | disclosed |
| US-6545103-B2 | Living polymers | FMC CORPORATION | 2003-04-08 | — | — | US | disclosed |
| US-6489337-B1 | TREATMENT OF ALZHEIMER'S DISEASE, EPILEPSY, EATING DISORDERS, LEARNING AND MEMORY DISORDERS, MIGRAINE, SLEEP/WAKE DISORDERS, ALLERGIC RHINITIS, SCHIZOPHRENIA, MILD COGNITIVE IMPAIRMENT, AND ASTHMA | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-12-03 | — | — | US | disclosed |
| US-6479487-B1 | INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS | AVENTIS PHARMACEUTICALS INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020010082-A1 | Compositions providing improved functionalization of terminal anions and processes for improved functionalization of terminal anions | FMC CORPORATION | 2002-01-24 | — | — | US | disclosed |
| WO-2001074813-A2 | METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
| EP-1056744-A1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| EP-1028982-A1 | COMPOSITIONS PROVIDING IMPROVED FUNCTIONALIZATION OF TERMINAL ANIONS AND PROCESSES FOR IMPROVED FUNCTIONALIZATION OF TERMINAL ANIONS | FMC CORPORATION (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999043675-A1 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| WO-1999025740-A1 | COMPOSITIONS PROVIDING IMPROVED FUNCTIONALIZATION OF TERMINAL ANIONS AND PROCESSES FOR IMPROVED FUNCTIONALIZATION OF TERMINAL ANIONS | FMC CORPORATION (US) | 1999-05-27 | — | — | WO | disclosed |
| US-4871745-A | LOCAL ANESTHETICS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-10-03 | — | — | US | disclosed |
| US-4791117-A | LOCAL ANTESTHETICS, ANTISECRETORY AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-12-13 | — | — | US | disclosed |
| EP-0261912-A2 | 2- or 3- Aryl substituted imidazo [1,2-a] pyridines | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-03-30 | — | — | EP | disclosed |
| US-4727145-A | LOCAL ANESTHETICS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-02-23 | — | — | US | disclosed |